EDIT vs NTLA
EDIT and NTLA side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEDITAS MEDICINE, INC. | NTLAINTELLIA THERAPEUTICS, INC. |
|---|---|---|
| Market cap | $409.29M | $1.75B |
| P/S | 10.1x | 25.8x |
| Revenue growth (YoY) | 25.4% | 16.9% |
| Earnings growth (YoY) | 32.5% | 20.5% |
| EBIT margin | -394.9% | -651.7% |
| ROE | -152.0% | -56.7% |
| 1y total return | -11.2% | +1.6% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: EDIT frente a NTLA
| Métrica | EDIT | NTLA |
|---|---|---|
| Valor final | $1.1K | $5.5K |
| Retorno total | -89.4% | -45.1% |
| CAGR | -19.5% | -5.6% |
| Volatilidad | 83.6% | 78.3% |
| Sharpe | 0.09 | 0.26 |
| Sortino | 0.14 | 0.39 |
| Caída máxima | -98.9% | -96.5% |
Basado en 2600 días de negociación comunes, 2016-06-29 → 2026-10-30 · tasa libre de riesgo 4.16% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)